Eckert & Ziegler SE (STU:EUZ) Beta: -0.2578 (As of Jun. 25, 2026)


STU:EUZ Eckert & Ziegler SE STU:EUZ
98 GF Score
Price €15.22
GF Value €16.10
Valuation Fairly Valued
View Full Analysis

What is Eckert & Ziegler SE Beta?

Eckert & Ziegler SE STU:EUZ -0.91% 98 Beta is -0.2578 as of Jun. 25, 2026. GuruFocus rates STU:EUZ with a GF Score™ of 98/100 and a GF Value™ of €16.10 (Fairly Valued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Eckert & Ziegler SE's Beta is -0.2578.


Eckert & Ziegler SE  (STU:EUZ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Eckert & Ziegler SE Beta Related Terms


Eckert & Ziegler SE Beta Historical Data

* Premium members only.

The historical data trend for Eckert & Ziegler SE's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eckert & Ziegler SE Beta Chart

Eckert & Ziegler SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 1.16 2.18 1.51 -0.42

Eckert & Ziegler SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.39 0.85 -0.42 0.01

STU:EUZ vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, Eckert & Ziegler SE's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eckert & Ziegler SE Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's Beta distribution charts can be found below:

* The bar in red indicates where Eckert & Ziegler SE's Beta falls into.


STU:EUZ
98GF Score
Eckert & Ziegler SE STU:EUZ
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eckert & Ziegler SE Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2578 mean?
Eckert & Ziegler SE (STU:EUZ) has a Beta of -0.2578 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Eckert & Ziegler SE and its competitors.
Is Eckert & Ziegler SE's Beta too high?
Eckert & Ziegler SE's current Beta is -0.2578. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's Beta compare to ABT and SYK?
Eckert & Ziegler SE's Beta of -0.2578 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Eckert & Ziegler SE and its competitors. Eckert & Ziegler SE's current Beta is -0.2578. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (STU:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.10, compared to a current price of €15.22 — trading 5.5% below its estimated fair value. The current Beta is -0.2578. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Eckert & Ziegler SE (STU:EUZ), the current Beta is -0.2578 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eckert & Ziegler SE (STU:EUZ) Overvalued in 2026?

Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued. The current stock price of €15.22 is trading 5.5% below its estimated GF Value™ of €16.10. GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.

Key valuation signals for STU:EUZ:

  • Beta: -0.2578
  • GF Value™: €16.10 vs. price of €15.22 (5.5% below fair value)
  • GF Score™: 98/100

No single metric tells the full story. See the STU:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eckert & Ziegler SE Business Description

Address Robert-Rossle-Street 10, Berlin, BB, DEU, 13125
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score

Get the complete analysis for STU:EUZ

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.22
Price
€16.10
GF Value